Trending...
- Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
- Community Partnership Brings Live Theater to 150+ Young People
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company's ongoing natural history study of adrenomyeloneuropathy (AMN) at the 8th Congress of the European Academy of Neurology (EAN) in Vienna. The intention of the CYGNET study is to assess disease progression in patients with AMN to inform the research and development of potential treatments, including SwanBio's lead candidate, SBT101, the first clinical-stage AAV-based gene therapy for AMN.
"At SwanBio, our approach to drug development begins with deepening our understanding of the origin and trajectory of diseases like AMN, ideally enabling us to deliver gene therapies that are both highly effective and meaningful for the quality of life of patients. With this in mind, our proprietary CYGNET study was designed to better characterize AMN disease progression, which varies from person to person," said Steven Zelenkofske, D.O., chief medical officer, SwanBio Therapeutics. "CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN."
SwanBio's CYGNET natural history study will track a number of variables over a two-year period, including:
More details about the CYGNET study, including demographics and disease characteristics of the first 21 patients enrolled, were presented during a virtual poster session at EAN.
More on The PennZone
SwanBio anticipates recruiting approximately 80 patients for the CYGNET natural history study; as of early June, the study was over 40% enrolled across five different global sites. Clinicians or patients interested in learning more about this study can review SwanBio's CYGNET flyer or contact SwanBio at clinicaltrials@swanbiotx.com.
Presentation Details
ePoster EPO-599: CYGNET: A prospective multicenter observational study of disease progression in patients with adrenomyeloneuropathy
Date & Time: June 27, 2022, 12:30 – 1:15 p.m. CEST
About SBT101
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation. In preclinical studies, treatment with SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AMN mouse models. SBT101 was also shown to be well-tolerated in non-human primates at six months post-treatment. The clinical program for SBT101 builds on this positive preclinical data, plus the company's already deep understanding of the underlying pathophysiology of the disease and the patient experience of AMN.
SwanBio expects to initiate a randomized, controlled Phase 1/2 clinical trial designed to assess the safety and efficacy of SBT101 in patients with AMN in the second half of 2022. In early 2022, the FDA cleared SwanBio's Investigational New Drug application for SBT101 and granted SBT101 Fast Track and Orphan Drug Designation.
More on The PennZone
About Adrenomyeloneuropathy
Adrenomyeloneuropathy (AMN) is a progressive and debilitating neurodegenerative disease caused by mutations in the ABCD1 gene that disrupt the function of spinal cord cells and other tissues. AMN is characterized by loss of mobility in adulthood, incontinence, pain, and sexual dysfunction, which all affect quality of life. Between 8,000-10,000 men in the United States and European Union are living with AMN. There are no approved therapies for the treatment of the disease; current standard of care is limited to symptom management.
About SwanBio Therapeutics
SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. SwanBio is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. SwanBio's lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. (lead investor and majority shareholder) and Mass General Brigham Ventures. For more information, visit SwanBioTx.com.
References
Contacts
Media Contact:
Lara Furst
+1-703-946-0183
media@swanbiotx.com
Investor Contact:
Chelcie Lister
+1-910-777-3049
investors@swanbiotx.com
Patient and Physician Inquiries:
clinicaltrials@swanbiotx.com
"At SwanBio, our approach to drug development begins with deepening our understanding of the origin and trajectory of diseases like AMN, ideally enabling us to deliver gene therapies that are both highly effective and meaningful for the quality of life of patients. With this in mind, our proprietary CYGNET study was designed to better characterize AMN disease progression, which varies from person to person," said Steven Zelenkofske, D.O., chief medical officer, SwanBio Therapeutics. "CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN."
SwanBio's CYGNET natural history study will track a number of variables over a two-year period, including:
- Body sway, which has been shown to be an early predictor of disease progression and likelihood of falls in AMN, even in asymptomatic patients.1
- Both traditional motor tasks and novel activity and sleep outcomes, using wearable technology.
- Quality of life and several disease severity and functional impairment measures.
More details about the CYGNET study, including demographics and disease characteristics of the first 21 patients enrolled, were presented during a virtual poster session at EAN.
More on The PennZone
- Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
- Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
- From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
- SKRAP Finds Hope Through Heartache on Powerful New Single "Shellshock"
SwanBio anticipates recruiting approximately 80 patients for the CYGNET natural history study; as of early June, the study was over 40% enrolled across five different global sites. Clinicians or patients interested in learning more about this study can review SwanBio's CYGNET flyer or contact SwanBio at clinicaltrials@swanbiotx.com.
Presentation Details
ePoster EPO-599: CYGNET: A prospective multicenter observational study of disease progression in patients with adrenomyeloneuropathy
Date & Time: June 27, 2022, 12:30 – 1:15 p.m. CEST
About SBT101
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation. In preclinical studies, treatment with SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AMN mouse models. SBT101 was also shown to be well-tolerated in non-human primates at six months post-treatment. The clinical program for SBT101 builds on this positive preclinical data, plus the company's already deep understanding of the underlying pathophysiology of the disease and the patient experience of AMN.
SwanBio expects to initiate a randomized, controlled Phase 1/2 clinical trial designed to assess the safety and efficacy of SBT101 in patients with AMN in the second half of 2022. In early 2022, the FDA cleared SwanBio's Investigational New Drug application for SBT101 and granted SBT101 Fast Track and Orphan Drug Designation.
More on The PennZone
- CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
- U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
- Valgar LLC Launches The Briefing Room: Education Leaders
- New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
- New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000
About Adrenomyeloneuropathy
Adrenomyeloneuropathy (AMN) is a progressive and debilitating neurodegenerative disease caused by mutations in the ABCD1 gene that disrupt the function of spinal cord cells and other tissues. AMN is characterized by loss of mobility in adulthood, incontinence, pain, and sexual dysfunction, which all affect quality of life. Between 8,000-10,000 men in the United States and European Union are living with AMN. There are no approved therapies for the treatment of the disease; current standard of care is limited to symptom management.
About SwanBio Therapeutics
SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. SwanBio is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. SwanBio's lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. (lead investor and majority shareholder) and Mass General Brigham Ventures. For more information, visit SwanBioTx.com.
References
- van Ballegoij WJC, van de Stadt SIW, Huffnagel IC, Kemp S, van der Knaap MS, Engelen M. Postural Body Sway as Surrogate Outcome for Myelopathy in Adrenoleukodystrophy. Front Physiol. 2020;11:786.
Contacts
Media Contact:
Lara Furst
+1-703-946-0183
media@swanbiotx.com
Investor Contact:
Chelcie Lister
+1-910-777-3049
investors@swanbiotx.com
Patient and Physician Inquiries:
clinicaltrials@swanbiotx.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
- Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
- Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
- Northeast Airlines Launches New Asset Management Group
- AI Visibility Labs LLC - Dallas Texas - July 16 2026
- NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
- ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
- Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
- Where Is Your Faith The Movie and Sountrack
- Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
- Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
- Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
- CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
- Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
- Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
- Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival
- Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
- Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
- Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
- Nevada Boxing Hall of Fame Gears Up for Star-Studded 14th Annual Induction Gala Weekend